Phase 3 Readout~month

Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta

Indication
Prostate Adenocarcinoma

Other upcoming events for CGON

Phase 3 ReadoutPhase 3 Topline: Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for
Phase 3 ReadoutPhase 3 Topline: Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radi
Phase 3 ReadoutPhase 3 Topline: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuva
Phase 3 ReadoutPhase 3 Topline: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futiba
Phase 3 ReadoutPhase 3 Topline: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta — CGON Phase 3 Readout | BioSniper